Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Maven Income and Growth VCT PLC has successfully completed an equity issue, raising a total of £10 million over the past two tax years. The company announced the final allotment of shares for the 2025/2026 tax year on Tuesday, with 1,376,139 new Ordinary Shares issued at prices ranging from 39.37p to 40.39p per share.
The equity issue, which commenced on 27 September 2024, was designed to generate up to £5 million, with the possibility of extending the offer by an additional £5 million through an over-allotment facility. The offer officially closed on 27 March 2025, with the company confirming it received £553,430 of valid applications in this final period.
With the latest issuance, the total number of Ordinary Shares in circulation has reached 183,107,666, equating to the same number of voting rights within the company.
Maven Income and Growth VCT PLC has also announced that it will be applying for the newly issued Ordinary Shares to be admitted to the Official List and to commence trading on the London Stock Exchange (LON:LSEG)’s main market for listed securities. The admission and the start of trading are expected to occur around 8 May 2025.
This move comes as part of the company’s broader strategy to provide investors with opportunities to invest in a range of private companies, with the aim of generating income and growth. The funds raised are indicative of investor confidence and a successful fundraising initiative by the company.
The information provided in this article is based on a press release statement from Maven Income and Growth VCT PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.